A Novel, Orally Delivered Antibody Therapy and Its Potential to Prevent Clostridioides difficile Infection in Pre-clinical Models

Clostridioides difficile infection (CDI) is a toxin-mediated infection in the gut and a major burden on healthcare facilities worldwide. We rationalized that it would be beneficial to design an antibody therapy that is delivered to, and is active at the site of toxin production, rather than neutrali...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberts, April K., Harris, Hannah C., Smith, Michael, Giles, Joanna, Polak, Oktawia, Buckley, Anthony M., Clark, Emma, Ewin, Duncan, Moura, Ines B., Spitall, William, Shone, Clifford C., Wilcox, Mark, Chilton, Caroline, Donev, Rossen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537341/
https://www.ncbi.nlm.nih.gov/pubmed/33072047
http://dx.doi.org/10.3389/fmicb.2020.578903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537341/
https://www.ncbi.nlm.nih.gov/pubmed/33072047
http://dx.doi.org/10.3389/fmicb.2020.578903

Ejemplares similares